Skip to main content
Caplight Logo









Caldera Therapeutics

Caldera Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttp://www.calderatx.com/

Last Round

Series A

Extension

Jan 14, 2026

Total Funding Raised

$112.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Caldera Therapeutics is a clinical stage biotechnology company developing CLD-423, a first-in-class bispecific antibody for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

bispecific antibodyIBD therapyinflammatory bowel diseaseIBDclinical stage biotechimmunologyfirst-in-class drugTL1A inhibitorIL-23 inhibitordual-target therapyulcerative colitisCrohn's diseasedrug licensingbiologicsPhase 1 clinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Caldera Therapeutics Comparables

Compare Caldera Therapeutics with similar companies based on industry and business-model similarity.

Caldera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bionyra Pharma
94%
TrueLab Biopharmaceutical
88%
Spyre Therapeutics Inc.
84%

Caldera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 14, 2026
Series AApr 23, 2025

Caldera Therapeutics Investors

Notable investors and investment history

Caldera Therapeutics investors
InvestorRounds
Janus Henderson GroupSeries A Extension
Omega FundsSeries A Extension
AccompliceSeries A Extension, Series A
venBioSeries A Extension, Series A
Wellington ManagementSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Monthly visitors grew 97% MoM, reaching 2K.

  • Jul 25, 2026

    Grew 63% QoQ, from 8 to 13 employees.

Caldera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Caldera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Caldera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range13
Year Founded2025
Last FundingJan 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?